checkAd

     162  0 Kommentare Kezar Provides Statement Regarding COVID-19 Pandemic

    SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today issued the following statement regarding the COVID-19 pandemic:

    We would like to express our sincerest gratitude for all of the healthcare workers and other responders on the frontlines working tirelessly to combat this global pandemic. This pandemic has affected us all, and we wanted to share Kezar’s response during this time of crisis and provide a brief update on our research and development activities and overall business operations.

    The health and safety of our employees and of those involved in our clinical trials is paramount. On March 10th, as the threat of COVID-19 became ever more evident, we recommended that our employees begin working from home. Our passionate team of professionals has adapted well, and work across the company has largely continued apace.

    Over the last few weeks, we have been in close communication with the investigators and site staff participating in our three clinical trials with KZR-616. While the situation is still rapidly evolving, it’s clear that everyone, everywhere is affected by this unprecedented health crisis. The feedback we are receiving from investigators speaks to different degrees of slowdown depending on the nature of the site and its geographic location. For example, private specialty clinics are often less impacted than large academic medical centers, which are currently unable to screen new patients as their resources are being realigned to care for patients with COVID-19. In addition, the severity of slowdowns varies from country to country. The diversity of our investigator base and an adequate drug supply has enabled us to keep our clinical trials with KZR-616 active at this time.

    As a result of this slowdown, we anticipate delays in our previously anticipated clinical development and data release milestones for KZR-616. However, as the Phase 1b portion of our MISSION study is open-label, we will continue to receive data during the course of 2020. The next updated data release for the Phase 1b portion is expected to occur in conjunction with a major medical conference by the end of the second quarter.

    Seite 1 von 4


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Kezar Provides Statement Regarding COVID-19 Pandemic SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and …